- Blood Sugar
- Clinical Studies
- Complementary Medicine
- Diabetes and Men
- Erectile Dysfunction
- Food and Nutrition
- Insulin Pumps
- Meters and Test Strips
- Product Recalls
- Type 1
- Type 2
- Weight Loss Surgery
Archive - 07 - 2013
July 26, 2013 (FDA) — Nova Diabetes Care today announced it is initiating a voluntary recall of 21 lots of the Nova Max Glucose Test Strips distributed both in the USA and outside the continental USA. Nova Max Plus™ glucose meter kits that include test strips from the recalled lots are also included in this voluntary recall. The company has recently determined that some of the blood glucose test strips contained within the indicated Nova Max Glucose Test Strip lots and Nova Max Plus glucose meter kits may report a false, abnormally high blood glucose result. Those who use, recommend clinically, or sell Nova Max Glucose Test Strips for blood glucose testing should immediately discontinue using or distributing glucose test strips from the recalled lots (see attached list). A false abnormally high blood glucose result could, under certain conditions, result in an insulin dosing error that could lead to a serious health risk requiring immediate medical attention. Customers can check to confirm if they have blood glucose test strips from the affected lots on the attached list, by visiting www.novacares.com/news/nova-max-recall.php or by contacting Nova Diabetes Care customer service at 1-800-681-7390. No other product or lot number from Nova Diabetes Care is impacted by this recall. Customers can contact Nova Diabetes Care customer service at 1-800-681-7390 to replace their affected test strip lot or meter kit at no charge. Customers may continue to test blood glucose using any other Nova Max Glucose Test Strip lot not indicated as part of this recall while waiting for their replacement to arrive. In the event that a customer must use affected test strips from the indicated lots above while waiting for replacement product to arrive, Nova Diabetes Care recommends customers take the following precautions: 1. As stated in the Blood Glucose Monitor Owners Guide and Nova Max Glucose Test Strip Product Insert, customers should perform a quality control solution test to confirm that the vial of Nova Max Glucose Test Strips is working correctly. 2. Customers should not use a test strip vial if control solution results are not within the expected range. 3. Customers should verify all elevated blood glucose test results that are not consistent with their diabetes history by repeating the test using a new blood glucose test strip from a different vial (if available) or the same vial (if a new vial is unavailable). 4. Customers should contact their health care provider immediately if their reported blood glucose result(s) are not consistent with their diabetes history, how they feel, or if they think their results are not accurate (higher than expected). Customers should never ignore symptoms or make significant changes to their diabetes management program without speaking to their health care professional. People with Diabetes should be aware of symptoms of high blood sugar (hyperglycemia) and low blood sugar (hypoglycemia). Customers should contact their healthcare professional for advice on how to treat the symptoms noted below. -Symptoms of high blood sugar include excessive thirst, excessive urination, blurred vision, weakness, nausea, vomiting, and abdominal pain.
-Symptoms of low blood sugar include trembling, excessive sweating, weakness, hunger, confusion, and headache. Some individuals may experience no symptoms before experiencing unconsciousness or seizures. It is important to treat low blood sugars promptly to avoid loss of consciousness or seizure. Upon identifying the issue, Nova Diabetes Care promptly notified all registered users, health care professionals, pharmacies, and distributors where the Nova Max Glucose Test Strip and Nova Max Plus glucose meter kit are recommended or sold. Nova Diabetes Care has reported this situation to the U.S. Food and Drug Administration and has taken the necessary corrective actions to prevent this situation from recurring. Nova Diabetes Care remains committed to providing patients and health care professionals with the highest quality products and services. We apologize for any inconvenience this issue may cause. Thank you for your continued support of Nova Diabetes Care products. For more information, visit www.novacares.com/news/nova-max-recall.php or contact Nova Diabetes Care customer service at 1-800-681-7390.
July 25, 2013 (Heriot-Watt Unversity) — Scientists believe the proteins that are targeted by cosmetic surgery treatment Botox could hold the secret to treating and even curing Type 2 diabetes. A team of researchers at Heriot-Watt University is using new molecular microscopic techniques on SNARE proteins to solve the mystery of how insulin release is regulated and how this changes during Type 2 diabetes. SNARE proteins SNARE proteins are targeted by Botox treatments, preventing them from helping muscles contract. However, their role goes well beyond the cosmetic realm, such as their work in the human pancreas. Dr Colin Rickman and his team are observing SNARE proteins in pancreatic beta-cells, the highly specialised cells that release insulin. Within the cells are SNARE proteins, which are the machinery that helps the beta-cells release the insulin to try and stabilise blood glucose levels. Type 2 diabetes occurs when the beta-cells can't cope with the prolonged high glucose levels of some obese patients and so secrete less insulin. The beta-cells lose both mass and function, but the reasons for this have always been unclear. The Heriot-Watt team hopes to answer these questions by observing SNARE proteins in the cell for the first time, pinpointing their exact location in an area equivalent to a ten-thousandth of a human hair. New methods of diagnosis for Type 2 diabetes Dr Colin Rickman said, "The human body has a system for storing glucose and releasing it when the body needs energy. This system controlled by the release of insulin. "When a person is obese, which a worryingly high and increasing number of people in the UK are, this system is put under pressure and eventually fails. This leads to Type 2 diabetes. "We know SNARE proteins are responsible for insulin secretion, but it's still not understood exactly how they do it. "Once we can understand how these proteins behave in ‘normal' circumstances, how they move, how they are arranged in the cell, how they interact with other proteins, we can then compare it with what happens under Type 2 diabetic conditions. This is the first time these proteins have ever been observed in such detail. "Ultimately this could lead to new methods of diagnosis, prevention of the cells' failure that leads to diabetes and also treatments for Type 2 diabetes." In 2012, the NHS described diabetes as ‘... one of the most prevalent and serious chronic conditions currently affecting the UK population'1. From 1996 – 2012, the number of people diagnosed with diabetes increased by 1.5 million. It is estimated that five million people will have diabetes in the UK by 2025, due in part to an ageing population and a dramatic increase in the number of overweight and obese people2. Dr Rickman and his team are funded by the Medical Research Council and the Edinburgh Super Resolution Imaging Consortium (ESRIC), a joint initiative between Heriot-Watt University and the University of Edinburgh. 1 http://www.nhs.uk/news/2012/04april/Pages/nhs-diabetes-costs-cases-rising.aspx 2 http://www.diabetes.org.uk/Documents/Reports/Diabetes-in-the-UK-2012.pdf
One in Ten AMI Patients Have Unrecognized Incident Diabetes
Two New LDL Cholesterol Drugs May Have Big Impact on Heart Disease
COBA Conference Steers Forward in the Fight Against Childhood Obesity
Google Secures Patent for Glucose-Sensing Contact Lens
Medtronic to Use GlucoSitter Artificial Pancreas Software in Future Insulin Pumps - A Big Deal!